UNSPSC 51261801: Afurolol

This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WQ1WRV49R9. European Medicines Agency schedules Afurolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05283MIG. Afurolol generally arises in the molecular formula C15H21NO4.

The term AFUROLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 33, no. 10 1979, list 19.) AFUROLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, AFUROLOL remains the US FDA Preferred Term for this commodity. Afurolol bears US NLM identifiers UMLS ID C2348000 and NCI Concept Code C72970. SMILES: O(CC(O)CNC(C)(C)C)C1C2C(COC2=O)CCC1.

UNSPSC 51261801 Afurolol, a Commodity code, shows limited recent state and local solicitation activity; the two opportunities posted under this code diverge markedly from its nominal pharmaceutical scope. Seminole County, Florida issued an IFB in June 2026 for naloxone and drug deactivation systems (1,900 units of naloxone and 800 safe drug deactivation systems annually), delivered quarterly to the county community health building, with shipping included and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted an RFI in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, focusing on negotiated net pricing and outcomes-based contracting models for self-insured employers and state agencies. These solicitations reflect community health and pharmacy program management activity rather than the specific pharmaceutical product the code nominally describes, signaling either a tagging mismatch or very narrow recent use of the code for state and local procurement.

Issuing bodies engaging under this code span health and human services functions at county and state levels. Florida's Seminole County represents municipal-scale health procurement; Texas HHS represents large-state health system procurement in an exploratory phase. Geographic activity centers on Florida and Texas with no supporting evidence of broader multi-state engagement. The Seminole County IFB (IFB60459723LAS, due July 26, 2023 per the source date discrepancy) requires electronic bid submission, drug-free workplace certification, E-Verify compliance, and standard insurance coverage, with potential FEMA funding introducing Clean Air Act and Federal Water Pollution Control Act compliance. The Texas RFI (HHS0017013, closed April 3, 2026) carries no binding timeline or award commitment and functions as market research to inform future RFP strategy; it specifies no set-asides or disadvantaged-enterprise restrictions at this preliminary stage.